Role of Key TYMS Polymorphisms on Methotrexate Therapeutic Outcome in Portuguese Rheumatoid Arthritis Patients

• Aurea Lima ,

  * E-mail: aurea.lima@iscsn.cespu.pt

  Affiliations CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Pharmaceutical Sciences, Higher Institute of Health Sciences-North (ISCS-N), Gandra PRD, Portugal, Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal, Abel Salazar Institute for the Biomedical Sciences (ICBAS) of University of Porto, Porto, Portugal

  ⨯
• Vítor Seabra,

  Affiliation CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Pharmaceutical Sciences, Higher Institute of Health Sciences-North (ISCS-N), Gandra PRD, Portugal

  ⨯
• Miguel Bernardes,

  Affiliations Faculty of Medicine of University of Porto (FMUP), Porto, Portugal, Rheumatology Department of São João Hospital Center, Porto, Portugal

  ⨯
• Rita Azevedo,

  Affiliations Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal, Faculty of Medicine of University of Porto (FMUP), Porto, Portugal

  ⨯
• Hugo Sousa,

  Affiliations Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal, Faculty of Medicine of University of Porto (FMUP), Porto, Portugal, Virology Service, Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal

  ⨯
• Rui Medeiros

  Affiliations Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal, Abel Salazar Institute for the Biomedical Sciences (ICBAS) of University of Porto, Porto, Portugal, Virology Service, Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal, Research Department-Portuguese League Against Cancer (LPCC-NRNorte), Porto, Portugal

  ⨯